WO2026067620A1 - Anticorps anti-dll3 à domaine unique et leurs utilisations - Google Patents

Anticorps anti-dll3 à domaine unique et leurs utilisations

Info

Publication number
WO2026067620A1
WO2026067620A1 PCT/CN2025/124373 CN2025124373W WO2026067620A1 WO 2026067620 A1 WO2026067620 A1 WO 2026067620A1 CN 2025124373 W CN2025124373 W CN 2025124373W WO 2026067620 A1 WO2026067620 A1 WO 2026067620A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
antibody
acid sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2025/124373
Other languages
English (en)
Inventor
Hui Yang
Jian Li
Chanjuan Liu
Xi Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TJ Biopharma (Shanghai) Co Ltd
Original Assignee
TJ Biopharma (Shanghai) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TJ Biopharma (Shanghai) Co Ltd filed Critical TJ Biopharma (Shanghai) Co Ltd
Publication of WO2026067620A1 publication Critical patent/WO2026067620A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des anticorps anti-DLL3 à domaine unique et des polypeptides comprenant les anticorps, tels que des anticorps bispécifiques et des récepteurs antigéniques chimériques. Ces anticorps ont une excellente affinité de liaison et sont efficaces pour induire une internalisation cellulaire médiée par des anticorps.
PCT/CN2025/124373 2024-09-29 2025-09-26 Anticorps anti-dll3 à domaine unique et leurs utilisations Pending WO2026067620A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2024/122280 2024-09-29
CN2024122280 2024-09-29

Publications (1)

Publication Number Publication Date
WO2026067620A1 true WO2026067620A1 (fr) 2026-04-02

Family

ID=99308151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2025/124373 Pending WO2026067620A1 (fr) 2024-09-29 2025-09-26 Anticorps anti-dll3 à domaine unique et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2026067620A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020076977A2 (fr) * 2018-10-11 2020-04-16 Inhibrx, Inc. Anticorps à domaine unique dll3 et compositions thérapeutiques
CN114057880A (zh) * 2021-11-10 2022-02-18 四川大学华西医院 一种dll3单克隆抗体
CN116041519A (zh) * 2022-12-27 2023-05-02 华道(上海)生物医药有限公司 一种抗dll3的纳米抗体、相关产品和用途
US20230227577A1 (en) * 2020-05-05 2023-07-20 Oncorus, Inc. Anti-dll3 antibodies and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020076977A2 (fr) * 2018-10-11 2020-04-16 Inhibrx, Inc. Anticorps à domaine unique dll3 et compositions thérapeutiques
US20230227577A1 (en) * 2020-05-05 2023-07-20 Oncorus, Inc. Anti-dll3 antibodies and methods of use
CN114057880A (zh) * 2021-11-10 2022-02-18 四川大学华西医院 一种dll3单克隆抗体
CN116041519A (zh) * 2022-12-27 2023-05-02 华道(上海)生物医药有限公司 一种抗dll3的纳米抗体、相关产品和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KRYTSKA KATERYNA, CASEY COLLEEN E., POGORILER JENNIFER, MARTINEZ DANIEL, RATHI KOMAL S., FARREL ALVIN, BERKO ESTHER R., TSANG MATT: "Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma", CANCER RESEARCH COMMUNICATIONS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 2, no. 7, 11 July 2022 (2022-07-11), pages 616 - 623, XP093412404, ISSN: 2767-9764, DOI: 10.1158/2767-9764.crc-22-0137 *
L. R. SAUNDERS, A. J. BANKOVICH, W. C. ANDERSON, M. A. AUJAY, S. BHEDDAH, K. BLACK, R. DESAI, P. A. ESCARPE, J. HAMPL, A. LAYSANG,: "A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo", SCIENCE TRANSLATIONAL MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, vol. 7, no. 302, 26 August 2015 (2015-08-26), pages 1 - 15, XP055288294, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aac9459 *

Similar Documents

Publication Publication Date Title
JP6449777B2 (ja) 抗ｎｔｂ−ａ抗体ならびに関連する組成物および方法
WO2024165056A1 (fr) Anticorps ciblant liv-1 et leurs utilisations
US20250313632A1 (en) Anti-b7-h3 antibodies and uses thereof
EP4736958A2 (fr) Anticorps anti-5t4 et leurs utilisations
US20250109200A1 (en) Antibodies and antibody-drug conjugates targeting claudin 6
WO2025011462A1 (fr) Anticorps à domaine unique pour gprc5d
WO2025108446A1 (fr) Anticorps anti-cdh17 et leurs conjugués
WO2025190281A1 (fr) Anticorps anti-dll3 et leurs utilisations
WO2024222863A1 (fr) Traitement combiné ciblant sirpa et claudine 18,2
WO2025237313A1 (fr) Anticorps anti-stn et conjugués associés
WO2026056954A1 (fr) Anticorps anti-folr1 et leurs conjugués
WO2026057016A1 (fr) Anticorps anti-nectine-4 et leurs conjugués
WO2025119346A1 (fr) Anticorps dépendant de l'anp
WO2025061132A1 (fr) Anticorps anti-dll3 et leurs utilisations
TW202535953A (zh) 靶向密連蛋白６之抗體及抗體－藥物結合物
HK40117975B (en) Anti-b7-h3 antibodies and uses thereof
HK40117975A (en) Anti-b7-h3 antibodies and uses thereof
HK40004147B (en) High affinity b7-h6 antibodies and antibody fragments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25872673

Country of ref document: EP

Kind code of ref document: A1